Article Information

Authors:
Madisa Mine1,2
Sikhulile Moyo2
Penny Stevens3
Kurt Michael3
Vladimir Novitsky2,6
Kgomotso Makhaola1,2
Aida Asmelash2
S’khatele Molefhabangwe2
Elias Woldegabriel2
Gaseboloke Mothowaeng2
Talkmore Maruta2
Charity Kamhukamwe1
Phibeon M. Mangwendeza2
Molly Holmes-Pretorius6
Isaac Mtoni1
Modisa Motswaledi4
Rosemary Musonda2
Ndwapi Ndwapi4
Joseph Makhema2
Richard Marlink2,6
Khumo Seipone5
Tendani Gaolathe2
Max Essex2,6

Affiliations:
1National Health Laboratory, Gaborone, Botswana

2Botswana-Harvard AIDS Institute Partnership (BHP), Princess Marina Hospital, Gaborone, Botswana

3Safety Monitoring in International Laboratories (SMILE), Johns Hopkins University, Baltimore, Maryland, United States

4Department of Clinical Services, Ministry of Health, Gaborone, Botswana

5Department of HIV/AIDS Prevention and Care, Ministry of Health, Gaborone, Botswana

6Harvard School of Public Health, Boston, Massachusetts,
United States

Correspondence to:
Madisa Mine

Postal address:
5353 Church Road, Extension 10, Gaborone, Botswana

Dates:
Received: 15 June 2011
Accepted: 11 Nov. 2011
Published: 15 Dec. 2011

How to cite this article:
How to cite this article: Mine M, Moyo S, Stevens P, et al. Immunohaematological reference values for HIV-negative healthy adults in Botswana. Afr J Lab Med. 2011;1(1), Art. #5, 7 pages. http://dx.doi.org/10.4102/
ajlm.v1i1.5

Copyright Notice:
© 2012. The Authors. Licensee: AOSIS OpenJournals.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Immunohaematological reference values for HIV-negative healthy adults in Botswana
In This Original Research...
Open Access
Abstract
Introduction
Materials and methods
   • Study design, setting and population
   • Study procedures
Laboratory procedures
   • Blood collection and HIV serology
   • Flow cytometric analysis
   • Haematological analysis
Ethical considerations
   • Statistical analysis
Results
Discussion
   • Limitations of the study
Conclusion
Acknowledgements
   • Competing interests
   • Authors’ contributions
References
Abstract

Background: Clinical laboratories in Botswana have relied entirely on the reference intervals for normal immunohaematological values provided by manufacturers’ kits and textbooks.

Objectives: The aim of this study was to determine the means, medians, 2.5th and 97.5th percentile reference intervals, for normal immunohaematological values in healthy adults in Botswana.

Method: A total of 261 healthy participants comprising 126 men (48%) and 135 (52%) women were enrolled in the southern part of Botswana, and immunological and haematological laboratory parameters were measured.

Results: The mean age was 28.8 (95% Confidence Interval [CI] 27.7–29.8) years, with a median of 27 years and a range 18–66 years. The mean haemoglobin level was significantly lower for women (12.4 g/dL; 95% CI 12.1% – 12.7%) than men (15.1 g/dL; 95% CI 14.9% – 15.3%). The women’s haemoglobin reference values (9.0 g/dL – 15.0 g/dL) levels were lower than observed in predominantly White populations (12.0 g/dL – 16.0 g/dL), but comparable with regional consensus reference intervals (9.5 g/dL – 15.8 g/dL) recently defined for East and Southern Africa.

Conclusion: The established values provide an important tool for patient management and could influence decisions on inclusion of participants and adverse events in clinical trials conducted locally.

Introduction

The human immunodeficiency virus (HIV) constitutes a major public health problem in Botswana with a prevalence of 17.6% 1 in the general population and 31.8% amongst pregnant woman.2,3 Botswana is one of the countries in Africa that has led a very high response to the epidemic through a range of multilevel interventions, including the widespread access to antiretrovirals (ARVs),4,5 and has built capacity to conduct international prevention, treatment and vaccine trials.6 A valid scientific safety evaluation of ARVs and HIV vaccines relies on the availability of locally defined reference values for parameters of clinical interest.7

Reference intervals are essential for monitoring patho-physiological changes after infection or disease states, or following the administration of drugs in therapeutic or clinical interventions and vaccine studies. Several multicenter trials, including Phase I and/or Phase II vaccine studies and global use of ARVs, have increased the need for regional and locally established reference values.8 Reference values vary considerably in different populations, geographical regions, climate, race and dietary habits.9,10,11,12,13,14,15 Reference intervals studies conducted in African countries have shown differences within populations and sometimes within sub-groups, and marked differences with values from White populations.8,13,16,17,18 These studies have also observed significant differences with values from developed countries, in haematologic parameters such as haemoglobin and absolute neutrophil, which are normally used for toxicity grading in clinical trials, and consequently have implications in patient management and the conduct of clinical trials.18,19,20,21 A significant number of potential African volunteers are excluded from participating in vaccine trials because screening, enrollment and follow-up monitoring is mostly based on values derived from predominantly White populations. A study in Uganda19 documented an exclusion rate of as high as 69% of vaccine clinical trial participants because of haematologic abnormalities, 83% of whom could have been included in the studies if local reference ranges were used. Kibiya et al.8 observed that the lower limit of neutrophil counts and haemoglobin reference ranges qualify to be graded as moderate and severe adverse events, respectively, according to the Division of AIDS (DAIDS) toxicity grading table.22

Determination of the CD4+ T-lymphocyte counts play a pivotal role on the initiation and monitoring of patients on highly active antiretroviral therapy (HAART); hence the urgent need for establishing CD4+ lymphocytes reference intervals for local populations. Some studies have observed that Black people and Afro–Caribbean people have lower total white cell counts, and neutrophil and platelet counts, than White people.9,23,24 Immunohaematological reference values for a healthy Botswanan population have never been established formally, whereas in many African countries, it is common practice to use reference values established in predominantly White populations, which may not be representative of the Botswanan population (which comprises mostly Black people). In order to conduct investigation drug (IND) and vaccine trials successfully, an assessment of the local reference intervals is required.25,26,27 The aim of this study was to establish the immunohaematological reference values in healthy adults in Botswana following the Clinical Laboratory Standards Institute (CLSI) (formerly NCCLS) guidelines28 in order to improve patient care, the participation of individuals in clinical trials and the evaluation of adverse events.

Materials and methods

Study design, setting and population
A cross sectional study was conducted amongst healthy adult volunteers that were recruited at the voluntary counselling and testing center (VCT) known as Tebelopele (a Setswana name that means ‘foresight’) from around Gaborone, the capital city of Botswana. Potential volunteers who tested HIV-negative in a parallel testing algorithm that used Determine HIV-1/2 (Abbott Laboratories, IL, USA) and UniGold HIV (Trinity Biotech, Ireland) rapid test kits, were recruited into the study. The rapid HIV results were confirmed in the laboratory by using two enzyme-linked immunosorbent assays as per national guidelines.

Study procedures
Potential apparently healthy HIV-negative volunteers who consented to participate in the study were included. A brief screening questionnaire was administered by experienced study nurses. The questionnaire was designed using the Clinical Laboratory Standards Institute (CLSI) guidelines28 (formerly NCCLS) and the following categories were excluded:

• pregnant
• breastfeeding
• patients who had been inpatients in a hospital or who had been subjectively ill during the last month
• patients receiving medical treatment
• patients who had a recent or recurrent infection, including HIV and malaria
• patients who had smoked in the hour before blood was drawn
• patients who had donated blood in the preceding month.

Participants had access to their HIV-testing results through voluntary counselling and testing protocol, and obtained all other results through a registered physician for review and referral to appropriate care. Participants with underlying clinical conditions were excluded from the analysis as well.

Laboratory procedures

Blood collection and HIV serology
Approximately 15 mL whole blood was collected from the cubital vein with a vacutainer system in K3EDTA. Samples were analysed on the day of collection. HIV status was further confirmed in plasma from the samples by using an enzyme-linked immunosorbent assays Vironostika HIV Uniform II plus O (BioMérieux France, Marcy l’Etoile, France) and Murex HIV-1.2.O Murex (Biotech, Dartford, UK) according to manufacturer’s instructions. A parallel algorithm was applied and the tests were performed at the Botswana Harvard HIV Reference Laboratory, following national guidelines that included confirmation with Western Blot or DNA PCR for all discordant results.

Flow cytometric analysis
T-lymphocyte subsets were analysed on a FACSCalibur flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, California) by using a four-colour immunofluorescence reagent (BD MultiTEST CD3 fluorescein isothiocyanate [FITC]/CD8, phycoerythrin [PE]/CD45, peridinin chlorophyll protein [PerCP]/CD4, allophycocyanin [APC]), and TruCOUNT tubes according to the manufacturer’s instructions. The list-mode data was acquired and analysed with MultiSET software (Becton Dickinson Immunocytometry Systems). The instrument used was validated prior to use and it was monitored daily with TRUcount controls materials; it was also enrolled in an external quality assurance scheme by the United Kingdom External Quality Assessment Scheme (UKNEQAS). Analysis was conducted by trained and competent personnel.

Haematological analysis
Haematology parameters were determined from whole blood by using the Sysmex XE-2100 (Sysmex, Kobe, Japan), according to the manufacturer’s instructions. The XE-2100 is capable of measuring 32 parameters, including the white blood cell (WBC) 5-part differential into lymphocytes, monocytes, eosinophils, neutrophils and basophils. It also provides a 14-parameter haemogram, as well as an integral reticulocyte analysis that includes an immature reticulocyte fraction, a nucleated red blood cell (NRBC) count and calculated parameters. These calculated parameters are, the mean corpuscular volume (MCV) (fL), the corpuscular haemoglobin (MCH) (pg), the mean corpuscular haemoglobin concentration (MCHC) (g/dL), and the RBC distribution width by standard deviation (RDW-SD) (fL). The accuracy and precision of the instrument was monitored daily by using commercial quality control materials, as well as quarterly through enrollment in an external quality assurance scheme by the College of American Pathologists (CAP). Trained and competent personnel performed the analysis.

Ethical considerations

The study was approved by the Health Research and Development Committee (HRDC) of the Ministry of Health in Botswana. Written informed consent was obtained from participants prior to their enrollment. Those people found to be HIV-positive were excluded from the study, and referred for HIV care and treatment clinics for further management. CD4 and haematology results that were obtained, were offered free of charge as per the Botswanan guidelines.

Statistical analysis
Reference intervals were calculated according to the CLSI guidelines document C28-A2 28 by applying non-parametric methods. The medians were calculated and reference values were determined as the 2.5th and 97.5th percentiles, respectively, of the distribution of reference values. The mean, median, and standard deviation values were calculated for each immunohaematological parameter. We used confidence ratio, which is the ratio of (average confidence interval width) to (reference interval), as described by Rhoads,29 to evaluate the impact of the sample size. CLSI recommends a minimum of 120 healthy patients per group. The non-parametric Mann-Whitney U test was used to determine any statistically differences between laboratory values for men and women. P-values < 0.05 were considered significant. All statistical analyses were carried out with EP Evaluator Release 8 (David G. Rhoads and Associates, Kennett Square, Pennsylvania, USA) and Stata 11.0 (SataCorp, College Park, Texas, USA).

Results

Screening and enrollment started in May 2008 and ended in June 2008. A total of 294 individuals were screened: 145 men (49%) and 149 women (51%). A total of 33 (11.2%) of screened volunteers were excluded, following enrollment based on defined exclusion criteria. The remaining 261 participants’ samples were included in the study, and comprised 135 women (51%) and 126 men (49%). The mean age was 28.8 (95% CI, 27.7–29.8) years, with a median of 27 and a range 18–66 years.

In our results (Table 1 and Table 2) we show the means, medians and 95th percentile reference values, according to gender, for CD4+ and CD8+ T-lymphocytes absolute values and percentages. The median CD4 cell count in the women (924 cells/mm3) was significant higher than in the men (744 cells/mm3), with p < 0.05. The calculated combined reference intervals for CD4+ and CD8+ T-lymphocytes were 261 cells/mm3 – 1667 cells/mm3 and 261 cells/mm3 – 1538 cells/mm3 for men, and 268 cells/mm3 – 1667 cells/mm3 for women (Table 1). The reference intervals for CD8+ T-lymphocytes (Table 2) were comparable to those obtained from a blood donor population. The study furthermore shows that the CD4% and CD8% reference intervals for women were 27–63, for men 27–60, and for both sexes 27–63 (Table 3). The CD8% reference intervals were 12–46 for women, 11–45 for men, and 11–46 for both sexes. The absolute CD4 and CD8 values for Botswana were lower than for most African countries (Table 4).

TABLE 1: CD4+ cell counts for healthy HIV-negative adults in Botswana.

TABLE 2: CD8+ cells counts for healthy HIV-negative adults in Botswana.

TABLE 3: CD4% and CD8% cells counts for healthy HIV-negative adults in Botswana.

TABLE 4: Comparison of ratio of CD4+ to CD8+ and absolute CD4+, CD8+ and lymphocyte counts between different populations.

Our research shows the reference intervals for the haematological parameters (mean; mean s.d; and 95% CI for mean, median, range 2.5th to 97.5th percentile) partitioned by gender (Table 5 and Table 6). The red blood cell (RBC) parameters (median haemoglobin, haematocrit, and RBC) and WBC were statistically different according to gender (p < 0.05). There were; however, no gender-specific differences observed for some white blood cell (WBC) subsets (neutrophils, eosinophils, lymphocytes, reticulocytes and basophils), except for monocytes (p = 0.0089). Our research also shows haematological reference intervals from this study and those from certain African countries14,16,18,19 and non-African populations (Table 7).30 The haemoglobin reference intervals were generally higher than in East Africa, but lower than those from Ethiopia and US-based comparison populations.

TABLE 5: Means, medians and 95th percentile reference intervals for haematological parameters for 261 HIV-negative adults in Botswana.

TABLE 6: Means, medians and 95th percentile reference intervals of white blood cell subset percentages for 261 HIV-negative adults in Botswana.

TABLE 7: Comparison of haematological parameters between different populations.

Discussion

The reference intervals for immunohaematological and clinical chemistry parameters, which may serve as Botswanan standards for the interpretation of laboratory results, were established from 260 HIV-negative participants (134 women [52%] and 126 men [48%]) aged 18–66 years, from around Gaborone. As expected, the percentage CD4+ and CD8+ T-lymphocytes varied less between women and men. Malone et al.31 reported large fluctuations in repeated CD4+ cell counts in HIV-positive patients and can be explained, in part, by CD4+ cell count diurnal cycle, and also by high variability in total lymphocyte counts. HIV-negative women have a higher average CD4+ T-lymphocytes count than men, which confirms the findings of Bussmann et al.32 The CD4 cell counts are lower in Botswana than those observed in East Africa and USA. This has obvious implications on the clinical staging of AIDS and the assessment for disease progression.

The significant gender difference in red blood cell count, haemoglobin and haematocrit, agrees with other studies16 and with the well-established fact that men have higher values for the red blood cell parameters than women, partly because of the influence of the hormone androgen on erythropoiesis, and partly because of menstrual loss. The red blood cell parameters for the Botswanan population were within the intervals for the Ethiopian population, even though the expectation was that altitude induces erythropoiesis, which has accounted for the red blood cell parameters of Ethiopia that were consistently higher than those of many other African countries.16

The median haemoglobin level was significantly lower for women than for men, which is consistent with previous findings.8,9,21,27 The female haemoglobin reference value (9.0 g/dL to 15.0 g/dL) levels were lower than observed in predominantly White populations (12.0 g/dL to 16.0 g/dL), but comparable with East African and Southern African regional consensus reference intervals (9.5 g/dL to 15.8 g/dL) recently defined for East and Southern Africa. The Division of AIDS (DAIDS) has haematological criteria for grading the severity of potential vaccine-related adverse events.22 White blood cell and platelet counts, and haemoglobin levels are used as inclusion and/or exclusion criteria in many clinical trials. The lower limit of Botswana’s normal female reference range for haemoglobin qualifies as a moderate adverse event and a significant proportion of the woman may not qualify to be enrolled for Phase I and/or Phase II vaccine trials.

The methodologies in this study are commonly used, and should serve well as guidelines for the represented population. Laboratories that wish to adopt these reference intervals should explore any differences in methodology, and should verify the transference and appropriateness of the reference intervals to their laboratory.

Limitations of the study
Although this study meets the minimum CLSI requirements for establishing valid reference intervals, it is be important to explore further geographic and ethic differences that may exist within the Botswanan population. One limitation of our study is that, despite our efforts to include only healthy subjects, the use of a questionnaire, as well as HIV screening and a review by a physician, it was not feasible to screen for all medical conditions that might have influenced the laboratory results. For instance, participants were not examined for other infections such as respiratory infections, recent transient gastroenteritis and sexually transmitted infections. All participants were adults drawn from voluntary counselling and testing facilities. When reporting reference values, the actual representativeness of the data is an important concern for the underlying population. As in most studies, we cannot totally exclude the possibility that there is some sampling bias because of use of a self-selecting population. Our analysis excluded participants who showed any signs or symptoms of disease, however, and it is thus likely that our data are representative of healthy adults from the southern region of Botswana. Gaborone is the capital city of Botswana and has a diversity of ethnic groups; consequently, reference values from this region are not likely to make a significant clinical difference. Because of access to a reference laboratory working under ISO and GCLP standards, it was not easy to include regions that are further away from the capital city, but this data is still considered to be a very important baseline for similar future studies. The data are also immediately applicable in studies and clinical care that is an improvement over the current practice of using reference values derived from elsewhere.

Conclusion

This is the first study in Botswana to document haematological reference intervals for healthy adults. Our study shows that clinical reference values developed within the region are more appropriate for the Botswanan population than those adopted from developed countries. The established values provide an important tool for patient management and could influence decisions on the inclusion of participants, as well as the management of adverse events. It could also improve scientific validity in clinical trials that are conducted locally and regionally.

Acknowledgements

The authors would like to thank the participants of this study for their time and patience. The authors also extend their gratitude to the Voluntary Counselling and Testing (VCT) management for availing the use of their facilities for the recruitment of the study participants. In addition, the authors would like to thank the Ministry of Health and Botswana Harvard Partnership for supporting the study. The project was also supported by Grant Number U01AI069456 from the National Institute of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.

Competing interests
The authors declare that they have no financial or personal relationship(s) which may have influenced them inappropriately in writing this article.

Authors’ contributions
M. Mine (National Health Laboratory), V.N. (Harvard School of Public Health), R. Marlink (Harvard School of Public Health) and M.E. (Harvard School of Public Health) conceived and designed the study, and M. Mine, S. Moyo (BHP Princess Marina Hospital), P.S. (Johns Hopkins University), K. Michael (Johns Hopkins University) and M.H.-P. (Harvard School of Public Health) wrote the article. S. Moyo and M. Mine analysed the data. Clinical support was provided by A.A. (BHP Princess Marina Hospital), N.N. (Ministry of Health), J.M. (BHP Princess Marina Hospital), K.S. (Ministry of Health), T.G. (BHP Princess Marina Hospital), E.W. (BHP Princess Marina Hospital) and I.M. (National Health Laboratory) (Medical doctors), and by S. Molefhabangwe (deceased) (BHP Princess Marina Hospital), as well as by G.M. (BHP Princess Marina Hospital) (Study Nurses and recruiters). K. Makhaola (National Health Laboratory), T.M. (Princess Marina Hospital), C.K. (National Health Laboratory), P.M.M. (BHP Princess Marina Hospital), R. Musonda (BHP Princess Marina Hospital) and M. Motswaledi (Ministry of Health) provided laboratory support.

References

1. Central Statistics Office/National AIDS Coordinating Agency (CSO/NACA). Botswana behavioural AIDS impact survey III. Gaborone, Botswana: Central Statistics Office/National AIDS Coordinating Agency; 2010.

2. Ministry of Health Botswana. 2007 Botswana ANC second generation HIV/AIDS sentinel surveillance. Technical report. De La Hoz Gomez F, Anderson MG, Bodika S, et al., editors. Gaborone, Botswana: Botswana Government Print; 2009.

3. PLoSMedicineEditors. A new vision for clinical trials in Africa. PLoS Med. 2004;1:e71. http://dx.doi.org/10.1371/journal.pmed.0010071, PMid:15630472, PMCid:539056

4. Ojikutu B, Makadzange AT, Gaolathe T. Scaling up ART treatment capacity: Lessons learned from South Africa, Zimbabwe, and Botswana. Curr Infect Dis Rep. 2008;10:69–73. http://dx.doi.org/10.1007/s11908-008-0012-0, PMid:18377818

5. Bussmann H, Wester CW, Ndwapi N, et al. Five-year outcomes of initial patients treated in Botswana’s national antiretroviral treatment program. AIDS. 2008;22:2303–2311. http://dx.doi.org/10.1097/QAD.0b013e3283129db0, PMid:18981769, PMCid:2853026

6. Excler JL. AIDS vaccine efficacy trials: Expand capacity and prioritize. Expert Rev Vaccines. 2006;5:167–170. http://dx.doi.org/10.1586/14760584.5.2.167, PMid:16608417

7. Food and Drug Administration (FDA). Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Rockville, MD: Botswana Government Print; 2007.

8. Kibaya RS, Bautista CT, Sawe FK, et al. Reference ranges for the clinical laboratory derived from a rural population in Kericho, Kenya. PLoS ONE. 2008;3:e3327. http://dx.doi.org/10.1371/journal.pone.0003327, PMid:18833329, PMCid:2553265

9. Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol. 1996;49:664–666. http://dx.doi.org/10.1136/jcp.49.8.664, PMid:8881919, PMCid:500612

10. Mazzaccara C, Labruna G, Cito G, et al. Age-related reference intervals of the main biochemical and hematological parameters in C57BL/6J, 129SV/EV and C3H/HeJ mouse strains. PLoS ONE. 2008;3:e3772. http://dx.doi.org/10.1371/journal.pone.0003772, PMid:19020657, PMCid:2582346

11. Lugada ES, Mermin J, Kaharuza F, et al. Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol. 2004;11:29–34. PMid:1471554, PMCid:321349

12. Saathoff E, Schneider P, Kleinfeldt V, et al. Laboratory reference values for healthy adults from southern Tanzania. Trop Med Int Health. 2008;13:612–625. http://dx.doi.org/10.1111/j.1365-3156.2008.02047.x

13. Tugume SB, Piwowar EM, Lutalo T, et al. Hematological reference ranges among healthy Ugandans. Clin Diagn Lab Immunol. 1995;2:233–235. PMid:7697535, PMCid:170134

14. Lawrie D, Coetzee LM, Becker P, Mahlangu J, Stevens W, Glencross DK. Local reference ranges for full blood count and CD4 lymphocyte count testing. S Afr Med J. 2009;99:243–248. PMid:19588777

15. Otahbachi M, Simoni J, Simoni G, et al. Gender differences in platelet aggregation in healthy individuals. J Thromb Thrombolysis. 2010;30:184–191. http://dx.doi.org/10.1007/s11239-009-0436-x, PMid:20039102

16. Tsegaye A, Wolday D, Otto S, et al. Immunophenotyping of blood lymphocytes at birth, during childhood, and during adulthood in HIV-1-uninfected Ethiopians. Clin Immunol. 2003;109:338–346. http://dx.doi.org/10.1016/j.clim.2003.08.008, PMid:14697749

17. Menard D, Mandeng MJ, Tothy MB, Kelembho EK, Gresenguet G, Talarmin A. Immunohematological reference ranges for adults from the Central African Republic. Clin Diagn Lab Immunol. 2003;10:443–445. PMid:12738646, PMCid:154963

18. Karita E, Ketter N, Price MA, et al. CLSI-derived hematology and biochemistry reference intervals for healthy adults in Eastern and Southern Africa. PLoS ONE. 2009;4:e4401. http://dx.doi.org/10.1371/journal.pone.0004401, PMid:19197365, PMCid:2632744

19. Eller LA, Eller MA, Ouma B, et al. Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials. PLoS ONE. 2008;3:e3919. http://dx.doi.org/10.1371/journal.pone.0003919, PMid:19079547, PMCid:2593783

20. Wells J, Shetty AK, Stranix L, et al. Range of normal neutrophil counts in healthy Zimbabwean infants: Implications for monitoring antiretroviral drug toxicity. J Acquir Immune Defic Syndr. 2006;42:460–463. http://dx.doi.org/10.1097/01.qai.0000224975.45091.a5, PMid:16810112

21. Lubega IR, Fowler MG, Musoke PM, et al. Considerations in using US-based laboratory toxicity tables to evaluate laboratory toxicities among healthy Malawian and Ugandan infants. J Acquir Immune Defic Syndr. 2010;55:58–64. http://dx.doi.org/10.1097/QAI.0b013e3181db059d, PMid:20588184, PMCid:3033212

22. Division of AIDS (DAIDS). The division of AIDS table for grading the severity of adult and pediatric adverse events (DAIDS AE Grading Table). USA: National Institutes of Health; 2004.

23. Bussmann H, Wester CW, Masupu KV, et al. Low CD4+ T-lymphocyte values in human immunodeficiency virus-negative adults in Botswana. Clin Diagn Lab Immunol. 2004;11:930–935. PMid:15358655, PMCid:515279

24. Lawrie D, Coetzee LM, Becker P, Mahlangu J, Stevens W, Glencross DK. Local reference ranges for full blood count and CD4 lymphocyte count testing. S Afr Med J. 2010;99. PMid:20459912

25. Mills E, Cooper C, Guyatt G, et al. Barriers to participating in an HIV vaccine trial: A systematic review. AIDS. 2004;18:2235. http://dx.doi.org/10.1097/00002030-200411190-00003, PMid:15577535

26. Gilmour JW, Stevens WS, Gray C, De Souza M. Laboratory expansion to large-scale international HIV preventive vaccine trials. Curr Opin HIV AIDS. 2007;2:201. http://dx.doi.org/10.1097/COH.0b013e3280eec77a, PMid:19372887

27. Stevens W, Kamali A, Karita E, et al. Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. PLoS ONE. 2008;3:e2043. http://dx.doi.org/10.1371/journal.pone.0002043, PMid:18446196, PMCid:2312327

28. National Committee for Clinical Laboratory Standards (NCCLS). How to define and determine reference intervals in the clinical laboratory: Approved guideline. 2nd ed. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000.

29. Rhoads DG. Understading reference intervals. In: Rhoads DG, editor. EP evaluator release 8 for evaluating clinical laboratory methods. Kennett Square, Pennsylavania: David G. Rhoads and Associates, Inc.; 2007.

30. Cabot RC, Harris NL, Shepard J-AO, et al. Normal reference laboratory values. N Engl J Med. 2004;351:1548–1563. http://dx.doi.org/10.1056/NEJMcpc049016, PMid:15470219

31. Malone JL, Simms TE, Gray GC, Wagner KF, Burge JR, Burke DS. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: Total lymphocyte count fluctuations and diurnal cycle are important. J Acquir Immune Defic Syndr. 1990;3:144–151. PMCid:1967309

32. Bussmann H, Wester CW, Masupu KV, et al. Low CD4+ T-Lymphocyte Values in human immunodeficiency virus-negative adults in Botswana. Clin Diagn Lab Immunol. 2004;11:930–935. PMid:15358655, PMCid:515279



Crossref Citations

No related citations found.